EXSIGHT VENTURES
  • Home
  • Companies
  • Team
  • Blog
  • Contact
  • Thesis

Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies

8/20/2020

0 Comments

 
One principle guides our investments: invest in companies that will improve patients' lives. We have found that the best founders and executive teams share that belief. From our first meeting to an email this week, the Trefoil Therapeutics team has consistently echoed that sentiment. Today they take a big step forward to meeting that goal by announcing that they have started the first clinical trial of their regenerative treatment for people with corneal endothelial dystrophies. Congratulations to them on this accomplishment!
Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells San Diego, CA – August 19, 2020 – Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. The Phase 1/2 trial (“INTREPID”) is designed to evaluate TTHX1114’s safety and ability to stimulate the regeneration of corneal endothelial cells lost due to CED when administered by intracameral (back of the cornea) injection. Continue reading

Watch CEO David Eveleth at OIS@AAO.
0 Comments



Leave a Reply.

    Author

    ExSight Ventures

    Archives

    January 2021
    December 2020
    August 2020
    July 2020
    June 2020
    February 2020
    December 2019
    October 2019
    August 2019
    July 2019
    February 2019
    September 2018
    August 2018
    July 2018

    View my profile on LinkedIn

    Categories

    All

    RSS Feed

 ©ExSight Ventures, LLC                    Privacy Policy                    Terms and Conditions          Disclaimer       
  • Home
  • Companies
  • Team
  • Blog
  • Contact
  • Thesis